Journal of Shanghai Jiao Tong University (Medical Science) >

2025 , Vol. 45 >Issue 9: 1194 - 1201

DOI: https://doi.org/10.3969/j.issn.1674-8115.2025.09.011

Clinical research

Clinicopathologic characteristics, gene mutation profile, and prognostic analysis of patients with adrenal diffuse large B-cell lymphoma

  • HE Jiayin ,
  • CHEN Siyuan ,
  • SHI Qing ,
  • ZHANG Muchen ,
  • YI Hongmei ,
  • DONG Lei ,
  • QIAN Ying ,
  • WANG Li ,
  • CHENG Shu ,
  • XU Pengpeng ,
  • ZHAO Weili
Expand
  • Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; State Key Laboratory of Medical Genomics; Shanghai Institute of Hematology, Shanghai 200025, China
QIAN Ying, E-mail: ljj10395502@163.com.
XU Pengpeng, E-mail: pengpeng_xu@126.com.

Received date: 2025-05-05

  Accepted date: 2025-06-19

  Online published: 2025-09-30

Supported by

National Natural Science Foundation of China(82130004);“Two-hundred Talents” Program of Shanghai Jiao Tong University School of Medicine(20230013)

Fold

Abstract

Objective ·To analyze the clinicopathologic characteristics, gene mutation profile, and prognostic factors of patients with adrenal diffuse large B-cell lymphoma (DLBCL). Methods ·From March 2002 to December 2022, a total of 105 patients with adrenal DLBCL admitted to Ruijin Hospital, Shanghai Jiao Tong University School of Medicine were retrospectively analyzed for their clinicopathological data, survival outcomes, and prognostic factors. Patients' gene mutation profiles were evaluated by targeted sequencing of 152 lymphoma-related genes. Results ·The median age of the patients was 62 (15‒82) years and the male-to-female ratio was 2.3∶1. Among them, 63 patients (60.0%) were over 60 years old, 22 patients (21.0%) had an Eastern Cooperative Oncology Group (ECOG) performance status of two or higher, 87 patients (82.9%) were staged Ann Arbor Ⅲ‒Ⅳ, 92 patients (87.6%) had elevated serum lactate dehydrogenase (LDH) levels (above the upper limit of reference), 84 patients (80.0%) had extranodal invasion in at least two organs, 67 patients (63.8%) were of non-germinal center B-cell (non-GCB) origin, and 95 patients (90.5%) had an international prognosis index (IPI) scored over 2. With a median follow-up of 28.3 (0.7‒191.9) months, the estimated 2-year overall survival (OS) rate and progression-free survival (PFS) rate were 68.3% and 53.1%, respectively. The estimated 5-year OS rate and PFS rate were 52.6% and 44.0%, respectively. Among 93 patients who could be evaluated for clinical outcomes, 62 (66.7%) got a complete response (CR). Univariate analysis and multivariate Cox analysis revealed that age over 60 years was an adverse prognostic factor for PFS, and ECOG performance status of two or higher was an adverse prognostic factor for both OS and PFS. Targeted gene sequencing in 46 adrenal diffuse DLBCL patients showed high mutation frequencies in lysine methyltransferase 2D (KMT2D; n=17, 37%), Pim-1 proto-oncogene, serine/threonine kinase (PIM1; n=17, 37%), MYD88 innate immune signal transduction adaptor (MYD88; n=15, 33%), CD79b molecule (CD79B; n=13, 28%), and BTG anti-proliferation factor 2 (BTG2; n=10, 22%). Conclusion ·Age over 60 years is an adverse prognostic factor for PFS, and ECOG performance status of two or higher is an adverse prognostic factor for both OS and PFS in patients with adrenal DLBCL. Patients exhibited high frequencies of KMT2D, PIM1, MYD88, CD79B, and BTG2 mutations, as well as an increased proportion of the MCD-like subtype.

Key words： diffuse large B-cell lymphoma (DLBCL); extranodal; adrenal gland; clinicopathologic characteristic; gene mutation; prognostic factor

Cite this article

HE Jiayin , CHEN Siyuan , SHI Qing , ZHANG Muchen , YI Hongmei , DONG Lei , QIAN Ying , WANG Li , CHENG Shu , XU Pengpeng , ZHAO Weili . Clinicopathologic characteristics, gene mutation profile, and prognostic analysis of patients with adrenal diffuse large B-cell lymphoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025 , 45(9) : 1194 -1201 . DOI: 10.3969/j.issn.1674-8115.2025.09.011

References

[1] SWERDLOW S H, CAMPO E, PILERI S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390.
[2] SEHN L H, SALLES G. Diffuse large B-cell lymphoma[J]. N Engl J Med, 2021, 384(9): 842-858.
[3] CHEN S Y, XU P P, FENG R, et al. Extranodal diffuse large B-cell lymphoma: clinical and molecular insights with survival outcomes from the multicenter EXPECT study[J]. Cancer Commun (Lond), 2025. DOI: 10.1002/cac2.70033.
[4] OLLILA T A, OLSZEWSKI A J. Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence[J]. Curr Treat Options Oncol, 2018, 19(8): 38.
[5] LAURENT C, CASASNOVAS O, MARTIN L, et al. Adrenal lymphoma: presentation, management and prognosis[J]. QJM, 2017, 110(2): 103-109.
[6] SWERDLOW S H, CAMPO E, HARRIS N L. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer, 2017.
[7] CHESON B D, FISHER R I, BARRINGTON S F, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol, 2014, 32(27): 3059-3068.
[8] ZHU J, MA J, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)[J]. Chin J Cancer Res, 2021, 33(3): 289-301.
[9] ALTINMAKAS E, ü????K-KESER F E, JEFFREY MEDEIROS L, et al. CT and 18F-FDG-PET-CT findings in secondary adrenal lymphoma with pathologic correlation[J]. Acad Radiol, 2019, 26(6): e108-e114.
[10] 邓建华, 李汉忠. 原发性肾上腺淋巴瘤的诊断与临床处理[J]. 协和医学杂志, 2020, 11(1): 91-95.
  DENG J H, LI H Z. Diagnosis and clinical treatment of primary adrenal lymphoma[j]. Medical Journal Of Peking Union Medical College Hospital, 2020, 11(1): 91-95.
[11] KIM Y R, KIM J S, MIN Y H, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)[J]. J Hematol Oncol, 2012, 5: 49.
[12] SHI Y K, HAN Y, YANG J L, et al. Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1, 085 WHO classified cases in a single institution in China[J]. Chin J Cancer Res, 2019, 31(1): 152-161.
[13] SHEN R, XU P P, WANG N, et al. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma[J]. Clin Transl Med, 2020, 10(7): e221.
[14] LIU Q X, ZHU Y, YI H M, et al. KMT2D mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-induced regulatory T cell trafficking via FBXW7-NOTCH-MYC/TGF-β1 axis[J]. Int J Biol Sci, 2024, 20(10): 3972-3985.
[15] SHEN R, FU D, DONG L, et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma[J]. Signal Transduct Target Ther, 2023, 8(1): 145.
[16] YOUNES A, SEHN L H, JOHNSON P, et al. Randomized phase Ⅲ trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma[J]. J Clin Oncol, 2019, 37(15): 1285-1295.
[17] XU P P, SHI Z Y, QIAN Y, et al. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study[J]. Lancet Healthy Longev, 2022, 3(7): e481-e490.
[18] MCDONNELL T, MULKERRIN E. Primary adrenal lymphoma[J]. N Engl J Med, 2021, 384(2): 165.
Options
Outlines

/

〈 〉